Currently, the COVID-19 outbreak is affecting the logistics and transportation of essential commodities, including vaccines and In-vitro Diagnostics(IVDs). Recently importers approached the Central Drug and Standards Control Organization (CDSCO) and shared with the concerned office about the difficulties related to vaccines and IVDs imports. These essential imported products are stuck at the ports as samples for quality verification related to imported batches cannot be sent to the notified laboratories due to lockdown declared by the government in India.
Looking into the importance of these products for the country’s population, CDSCO released the notification for release of vaccines, IVDs and blood products (sampled 100% testing) from the ports after reviewing the documents, protocol, certificate of release batch by the manufacturer and past satisfactory history of the product. This will depend on the fulfillment of below-mentioned conditions.
CDSCO requested the port officers of the country to follow this procedure in the notification for easier availability of the essential vaccines, in vitro diagnostics, and blood products for the benefit of the country’s population. The nationwide lockdown for COVID-19 pandemic has created challenges at various levels like logistics, less manpower at each level, including the notified laboratories, however our regulatory authorities are taking important steps to make it easier and seamless for the importers and consumers.
Release of consignments of Vaccine and critical IVDs-certain instructions issued.pdf. Available at: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTc4OA==.Accessed on April 05, 2020.
The Strategic Shift For most global Cosmetic brands, India’s regulatory journey has begun with import registration — the COS-2 pathway explored throughout this series. But for a growing ..
Regulatory approval is often treated as the finish line. In reality, for Medical Device and IVD manufacturers in India, it marks the start of an equally demanding obligation: Post-Market Surveillance ..
One of the most avoidable and expensive mistakes in Medical Device commercialisation is Regulatory rework — the process of going back to redo documentation, testing, or submissions because the..
India
Global
Sales: +91 7672005050
Reception: +91-11-45214546
9 am to 6 pm (Monday to Friday)